Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PYPD

Polypid Ltd

Dec 13 • 04:00PM ET

2.61

Dollar change +0.03
Percentage change 1.16	%

Healthcare • Biotechnology • Israel • NASD

Peers: XTLB MRNS ANIP ATHE EPIX AVDL BCTX AUTL IMUX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.69	Insider Own	51.80%	Shs Outstand	6.80M	Perf Week	-13.58%
Market Cap	17.75M	Forward P/E	-	EPS next Y	-2.59	Insider Trans	0.00%	Shs Float	3.28M	Perf Month	-23.24%
Income	-26.86M	PEG	-	EPS next Q	-1.08	Inst Own	28.26%	Short Float	0.45%	Perf Quarter	-24.68%
Sales	0.00M	P/S	-	EPS this Y	71.63%	Inst Trans	-	Short Ratio	1.22	Perf Half Y	-35.56%
Book/sh	0.32	P/B	8.23	EPS next Y	46.06%	ROA	-132.55%	Short Interest	0.01M	Perf Year	-35.16%
Cash/sh	1.43	P/C	1.83	EPS next 5Y	-	ROE	-943.05%	52W Range	2.58 - 9.20	Perf YTD	-31.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-439.72%	52W High	-71.63%	Beta	1.35
Dividend TTM	-	Quick Ratio	1.00	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1.16%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	1.00	EPS Y/Y TTM	-85.67%	Oper. Margin	-	RSI (14)	28.66	Volatility	11.38% 7.48%
Employees	62	Debt/Eq	4.64	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	11.75
Option/Short	No / Yes	LT Debt/Eq	1.83	EPS Q/Q	64.08%	Payout	-	Rel Volume	2.65	Prev Close	2.58
Sales Surprise	-	EPS Surprise	-21.70%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	12.18K	Price	2.61
SMA20	-18.36%	SMA50	-21.86%	SMA200	-36.57%	Trades		Volume	32,309	Change	1.16%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-14-21	Initiated	JMP Securities	Mkt Outperform	$14
Jul-30-21	Initiated	Cantor Fitzgerald	Overweight	$24
Nov-24-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-10-20	Initiated	Alliance Global Partners	Buy	$27
Jul-21-20	Initiated	Raymond James	Outperform	$23
Jul-21-20	Initiated	BMO Capital Markets	Outperform	$30
Jul-21-20	Initiated	Barclays	Overweight	$22

Dec-12-24 07:16AM	PolyPid announces research, development collaboration with ImmunoGenesis (TipRanks) -7.53%
Dec-11-24 07:00AM	PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy (GlobeNewswire)
Nov-29-24 01:05PM	PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance (GlobeNewswire)
Nov-14-24 02:08AM	PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-13-24 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
07:00AM	Loading…
Nov-07-24 07:00AM	PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference (GlobeNewswire)
Oct-30-24 08:00AM	PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 (GlobeNewswire)
Oct-23-24 07:01PM	Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd (GuruFocus.com) +5.59%
Oct-21-24 07:00AM	PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery (GlobeNewswire) -8.08%
Oct-01-24 07:00AM	PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Sep-03-24 07:00AM	PolyPid to Participate in Three Upcoming Fall Investor Conferences (GlobeNewswire)
Aug-14-24 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 08:31PM	PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds (GlobeNewswire)
Jul-31-24 07:00AM	PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 (GlobeNewswire)
Jun-18-24 07:00AM	PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial (GlobeNewswire)
07:00AM	Loading…
Jun-10-24 07:00AM	PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX100 Phase 3 Trial (GlobeNewswire)
May-10-24 05:25PM	PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.39% -8.22%
May-08-24 11:56AM	PYPD Stock Earnings: PolyPid Beats EPS for Q1 2024 (InvestorPlace) -11.32%
07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 07:00AM	PolyPid to Participate in Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-24 07:00AM	PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Apr-24-24 07:00AM	PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024 (GlobeNewswire)
Feb-28-24 07:00AM	PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference (GlobeNewswire) +8.68%
Feb-19-24 12:00PM	PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Feb-15-24 09:41AM	PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-24 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -8.21%
Feb-12-24 07:00AM	PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial (GlobeNewswire)
Jan-31-24 07:00AM	PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024 (GlobeNewswire)
Jan-04-24 04:32PM	PolyPid Announces Private Placement for $16 Million in Gross Proceeds (GlobeNewswire) -5.67% +16.36%
Nov-12-23 10:40AM	PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Loading…
Nov-08-23 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 07:00AM	PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors (GlobeNewswire) +7.88%
Nov-01-23 07:00AM	PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023 (GlobeNewswire)
Oct-11-23 07:00AM	PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule (GlobeNewswire)
Oct-09-23 07:00AM	PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023 (GlobeNewswire)
Oct-04-23 07:00AM	PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX and PLEX Technology Platform (GlobeNewswire)
Sep-22-23 07:00AM	PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) -9.24%
Sep-21-23 07:34AM	PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health (GlobeNewswire) -11.74%
Sep-20-23 09:15AM	PolyPid Announces Reverse Share Split (GlobeNewswire) +22.06%
Sep-19-23 07:00AM	PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX (GlobeNewswire) -10.00%
Aug-09-23 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire) -11.73%
Jul-26-23 07:00AM	PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023 (GlobeNewswire)
Jun-29-23 08:00AM	PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections (GlobeNewswire)
Jun-22-23 07:00AM	PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX for Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Jun-05-23 04:02PM	PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market (GlobeNewswire)
May-22-23 09:00AM	PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX for Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire) -6.26%
May-13-23 12:30PM	PolyPid Ltd. (NASDAQ:PYPD) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-10-23 07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 07:00AM	PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023 (GlobeNewswire)
Apr-24-23 07:00AM	PolyPid to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-14-23 04:01PM	PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders Equity Non-Compliance (GlobeNewswire) +5.01%
Mar-31-23 12:00PM	PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds (GlobeNewswire) +6.26%
Mar-29-23 07:59AM	PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants (GlobeNewswire) -16.86%
Mar-28-23 04:05PM	PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares (GlobeNewswire)
Mar-07-23 08:00AM	PolyPid to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +5.34%
Feb-09-23 03:22PM	PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-08-23 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -12.81%
Jan-31-23 07:00AM	PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023 (GlobeNewswire)
Jan-24-23 07:00AM	PolyPid Provides Positive Regulatory Update for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery (GlobeNewswire) +10.20%
Jan-03-23 07:00AM	PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire) +6.95%
Dec-12-22 07:00AM	PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery (GlobeNewswire)
Dec-09-22 04:01PM	PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire) -6.16%
Nov-29-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association (GlobeNewswire)
Nov-09-22 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -9.59%
Oct-26-22 07:00AM	PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022 (GlobeNewswire)
Oct-20-22 07:09AM	PolyPid Announces Cost Reduction Plan (GlobeNewswire)
Sep-28-22 08:57AM	PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire)
Sep-19-22 07:00AM	PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire)
Sep-12-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the European Society for Coloproctology Scientific Conference (GlobeNewswire) +58.33%
Sep-06-22 03:25PM	This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout (Benzinga) -19.58%
Sep-02-22 10:04AM	PolyPid's Lead Program Flunks Abdominal Surgery Study, Shares Tank (Benzinga) -73.47%
08:37AM	PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire)
Aug-31-22 09:55AM	Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet (Zacks) -5.64%
09:40AM	Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-30-22 07:00AM	PolyPid Announces Presentation at the 2022 Military Health System Research Symposium (GlobeNewswire)
Aug-15-22 12:00PM	All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy (Zacks) +5.13%
09:55AM	Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade (Zacks)
Aug-10-22 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 07:00AM	PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX in Europe (GlobeNewswire) +7.83%
Jul-27-22 07:00AM	PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022 (GlobeNewswire) +5.97%
Jul-25-22 07:00AM	PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the Midwest Surgical Association 2022 Annual Meeting (GlobeNewswire) +8.09%
Jul-05-22 07:00AM	PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO (GlobeNewswire) -5.29%
Jun-15-22 07:00AM	PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections (GlobeNewswire) +7.59%
Jun-06-22 07:00AM	PolyPid Announces Presentation of D-PLEX Phase 2 Clinical Data at ASM Microbe 2022 (GlobeNewswire)
Jun-02-22 07:00AM	PolyPid to Present at the JMP Securities 2022 Life Sciences Conference (GlobeNewswire)
Jun-01-22 07:00AM	PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects (GlobeNewswire)
May-31-22 07:00AM	PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery (GlobeNewswire) +7.60%
May-23-22 12:04PM	Why PolyPid Shares Are Gaining Today (Benzinga)
07:00AM	PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis (GlobeNewswire)
May-16-22 09:55AM	Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 289%: Read This Before Placing a Bet (Zacks) -8.60%
May-11-22 07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
Apr-27-22 07:00AM	PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022 (GlobeNewswire)
Apr-25-22 07:30AM	PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine (GlobeNewswire)
Apr-12-22 08:00AM	PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting (GlobeNewswire)
Apr-06-22 07:00AM	PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility (GlobeNewswire)
Mar-28-22 02:11PM	We Think PolyPid (NASDAQ:PYPD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-08-22 07:00AM	PolyPid to Deliver Poster Presentation at SAGES 2022 (GlobeNewswire)
Mar-02-22 07:00AM	PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX in Abdominal Surgery (GlobeNewswire) +13.33%
Mar-01-22 07:00AM	PolyPid to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +11.39%

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PYPD

Polypid Ltd

Upgrade your FINVIZ experience